Research Article
Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis
Table 1
MDS patient demographic and diagnostic data.
| | Age | Sex | Hct | Plts | ANC | Blast % | Cytogenetics | Diagnosis | IPSS | PB | MRW |
| 1 | 58 | M | 38 | 66 | 1.7 | 0 | 0 | t(1;7) | Hypocellular RCMD | Int-2 | 2 | 72 | M | 24 | 91 | 5.5 | 0 | 4 | (−5, −7) | RCMD | Int-2 | 3 | 75 | F | 25 | 13 | 4.3 | 0 | 0.5 | 1 abnormal cell | RCMD-RS | Int-1 | 4 | 59 | M | 32 | 134 | 0.8 | 0 | 13 | (20q-, −5, +14) | RAEB-2 | High |
| 5 | 62 | M | 28 | 35 | 0.9 | 0 | <5 | (−7) | 2° MDS, retic fibr | Int-2 | 6 | 5 | F | 24 | 49 | 0.9 | 0 | <0.5 | 46XX | RCMD | Int-1 | 7 | 59 | M | 26 | 12 | 1.8 | 0 | <0.5 | 46XY | RCMD | Int-1 | 8 | 82 | F | 24 | 27 | 1.1 | 0 | <5 | no metaphases | MDS with retic fibr | Int-1 | 9 | 65 | F | 38 | 97 | 2.1 | 0 | 1.5 | (−5) | RCMD | Int-1 | 10 | 52 | F | 21 | 366 | 3.5 | 0 | 3.5 | 46XX | RCMD | Low |
| 11 | 63 | M | 30 | 20 | 0.8 | 4 | 11 | (−5, −7), other | RAEB-2 | High | 12 | 65 | F | 26 | 23 | 0.7 | 0 | 6 | 46XX | RAEB-1 | Int-1 | 13 | 67 | F | 24 | 13 | 0.03 | 0 | 8 | (−5, 20q-) | RAEB-1 | Int-2 | 14 | 58 | M | 26 | 66 | 0.1 | 0 | 12 | (20q-) | RAEB-2 | Int-2 | 15 | 64 | M | 27 | 51 | 0.2 | 0 | 11 | t(3; 21) | RAEB-2 | High |
| 16 | 38 | F | 35 | 208 | 0.7 | 0 | 0.5 | 46XX | RCMD | Low | 17 | 58 | M | 27 | 15 | 0.05 | 0 | 11 | (20q-) | RAEB-2 | Int-2 | 18 | 20 | M | 37 | 23 | 0.2 | 0 | <0.5 | (−7) (familial) | RCMD | Int-2 | 19 | 81 | M | 30 | 178 | 3.5 | 0 | 1.5 | 46XY | RCMD | Low |
|
|
Hct: % hematocrit; Plts: platelets (thousands/microliter); ANC: absolute neutrophil count (thousands/microliter); PB: peripheral blood; MRW: marrow; retic fibr: reticulin fibrosis; RCMD: refractory cytopenia with multilineage dysplasia; RAEB: refractory anemia with excess blasts; IPSS: International Prognostic Scoring System for MDS; Int: intermediate.
|